Sun, Jun 8, 2025
Zeinab Siahmargoie1 
, Mohammad taher Hojjati2 , Hadi Bazzazi3 , Khodaberdi Kalavi3 , Mana Zakeri4 , Hadi Joshaghani3
, Mohammad taher Hojjati2 , Hadi Bazzazi3 , Khodaberdi Kalavi3 , Mana Zakeri4 , Hadi Joshaghani3
1- Iranian blood transfusion Organization, Gorgan branch, Iran
2- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,mthhematology@gmail.com
3- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4- department of medical genetics, faculty of medicine, hormozgan university of medical sciences, bandar abbas, iran
2- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran ,
3- Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4- department of medical genetics, faculty of medicine, hormozgan university of medical sciences, bandar abbas, iran
Abstract: (363 Views)
Background: Polycythemia Vera (PCV) is a type of myeloproliferative neoplasm (MPN) in which the progenitors of the erythroid lineage become overactive and produce large amounts of red blood cells (RBCs). More than 90% of people with PCV have a Janus kinase 2 (JAK2) gene mutation. In this study, we examined the status of possible JAK2 gene mutations in people with higher-than-normal hemoglobin (Hb) levels that physicians introduced to the laboratory.
Methods: In this descriptive cross-sectional study, JAK2 alleles were tested for possible JAK2 mutations in genomic DNA of 72 cases using a TaqMan-specific probe.
Results: Out of 72 patients, 24 were women (33.3%) and 48 (66.6%) were men, among them 39 (54.2%) were negative and 33 cases (45.5%) were positive for JAK2 mutation. The data also showed that 15 out of 24 female patients (62.5%) had positive JAK2 mutation, while in the male patients, 18 out of 48 (37.5%) were positive for JAK2 mutation.
Conclusion: According to our research, investigation of the Jak2 mutation, especially in women who had Hb levels upper than normal, seems to be necessary.
Methods: In this descriptive cross-sectional study, JAK2 alleles were tested for possible JAK2 mutations in genomic DNA of 72 cases using a TaqMan-specific probe.
Results: Out of 72 patients, 24 were women (33.3%) and 48 (66.6%) were men, among them 39 (54.2%) were negative and 33 cases (45.5%) were positive for JAK2 mutation. The data also showed that 15 out of 24 female patients (62.5%) had positive JAK2 mutation, while in the male patients, 18 out of 48 (37.5%) were positive for JAK2 mutation.
Conclusion: According to our research, investigation of the Jak2 mutation, especially in women who had Hb levels upper than normal, seems to be necessary.
Research Article: Research Article |
Subject:
Laboratory hematology
Received: 2023/11/4 | Accepted: 2024/04/6
Received: 2023/11/4 | Accepted: 2024/04/6
References
1. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. CMAJ. 2020;192(32):E913-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. CMAJ. 2020;192(32):E913-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Aladağ E, Aksu S, Demiroğlu H, Sayınalp N, Göker H, Haznedaroğlu IG, et al. Unclassifiable non-CML classical myeloproliferative diseases with. microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency. Turk J Med Sci. 2019;49(5):1560-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Alvarez-Larrán A, Ancochea A, Angona A, Pedro C, García-Pallarols F, Martínez-Avilés L, Bellosillo B, Besses C. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97(11):1704-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Hematol, Saeidi K. Myeloproliferative neoplasms: current molecular biology and genetics. Crit Rev Oncol Hematol. 2016:98:375-89. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005;11(12):546-54. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120(13):2704-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, et al. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2014;14(6):525-33. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Hamid M, Shahbazi Z. Prevalence of JAK2 V617F Mutation in Iranian Patients with Myeloproliferative Neoplasms. Arch Med Lab Sci. 2020;6(1):1-7. [View at Publisher] [DOI] [Google Scholar]
12. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol. 2015;141(12):2131-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15(4):173-89. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118(4):1071-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Nasseri M, Keyfi F, Rahbarian R, Rajabian M, Abbaszadegan MR. Examining the Frequency of the JAK2 (V617F) Mutation in Patients with Myeloproliferative Diseases in North Eastern Iran and the Effect of Treatment Intervention. Rep Biochem Mol Biol. 2020;9(2):188-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Gulbay G, Yesilada E, Erkurt MA, Gozukara Bag H , Kuku I, Kaya E. Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia. Turk J Biochemist. 2019;44(4):492-8. [View at Publisher] [DOI] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.